Form 4: Nuwellis Director Gregory Waller Receives Stock Options

Director Gregory D. Waller was granted 6,744 nonstatutory stock options in Nuwellis, Inc. as part of standard compensation.

Summary

• Director Gregory D. Waller acquired 6,744 nonstatutory stock options on April 28, 2026.
• The options have an exercise price of $1.16 per share.
• The options are set to expire on April 27, 2036.
• Vesting occurs in 12 equal monthly increments starting one month after the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $1.16 exercise price.

Future Outlook

The options vest over a 12-month period, indicating a commitment to the company's performance over the coming year.

Management Comments

• No specific management commentary provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to incentivize long-term oversight and strategic alignment in the medical device sector.

Comparison to Industry Standards

• The use of 12-month vesting schedules for director equity is consistent with standard industry practices for small-cap medical technology firms.

Stakeholder Impact

• Minor impact on share structure due to the issuance of new options.

Next Steps

• Vesting of options in 12 monthly increments starting May 2026.

Key Dates

Keywords

Nuwellis, NUWE, Director Compensation, Stock Options, Insider Transaction, Form 4